• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Zoetis Releases 2023 Sustainability Report to Share Progress in Building a Better Future for Communities, Animals and the Planet

    6/5/24 9:00:00 AM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ZTS alert in real time by email
    • Increased colleague-reported volunteer work by 81% to 16,611 hours
    • Through $8.3 million in grants, the Zoetis Foundation supported 28 initiatives impacting 19 countries to advance opportunities for veterinarians and livestock farmers through education, well-being, and livelihood initiatives
    • Brought to market innovative diagnostics, vaccines and parasiticides to support livestock producers' animal health and productivity goals
    • More than 30% of the company's total electricity use was supplied by renewable sources which includes on-site solar arrays installed at seven facilities – moving Zoetis toward its goal to use 100% renewable electricity by 2030
    • Replaced plastic with paperboard for rabies vaccine packaging at a key manufacturing site, cutting PVC plastic use by 8.0 metric tons and overall packaging by an estimated 2.5 metric tons annually

    Zoetis Inc. today published its 2023 Sustainability Report "Advancing Sustainability in Animal Health for a Better Future," to highlight the company's progress in achieving its Driven to Care long-term sustainability aspirations and provide continued disclosure on environmental, social and governance (ESG) topics. The report shares Zoetis' actions to meet aspirations across three pillars: Communities, Animals and Planet. Included in the report is the company's Sustainability Accounting Standards Board (SASB) and ESG Index, which provides relevant performance indicators, including those identified by SASB for the healthcare – biotechnology and pharmaceuticals industry. This Index also includes Zoetis' commitment to disclosing progress aligned with the Taskforce on Climate-related Financial Disclosure (TCFD), plus a link to the 2023 CDP Climate Change Questionnaire.

    "Our sustainability aspirations are an extension of our purpose at Zoetis, and we continue to make significant progress by embedding our sustainability strategy across our business as we build a healthier future for our communities, animals and the planet we share," said Jeannette Ferran Astorga, Executive Vice President, Corporate Affairs, Communications and Chief Sustainability Officer at Zoetis and President of the Zoetis Foundation. "Animal health has emerged as a clear climate solution with the Food & Agriculture Organization identifying measures – including genetics, vaccinations and improved access to veterinary care – which can ultimately improve health and productivity of animals and reduce global livestock greenhouse gas emissions."

    Communities – Care and Collaboration

    Zoetis invested $7 million in communities through corporate giving initiatives in 2023. These included partnering with Adopt a Pet to improve access to resources for pets, shelters, rescues and veterinary healthcare teams across the United States, an initiative in Indonesia to vaccinate cats and dogs against rabies, and earthquake relief efforts to support rescue and care of horses in Morocco. In total, the company's community programs reached approximately 202,000 pet owners in need and approximately 91,000 animals impacted by disaster. For its part, the Zoetis Foundation distributed $8.3 million in grants supporting 28 initiatives across 19 countries in 2023, including grants of $3 million to organizations that awarded scholarships to more than 500 veterinary students. This brings the Foundation's cumulative grant support to $14.9 million of its commitment to $35 million in grants from 2021 until the end of 2025. The funding supports the education, well-being and livelihoods of veterinarians and livestock farmers as well as humanitarian aid and a U.S. matching gifts program.

    In recognition of its commitment and actions in 2023 to foster an inclusive culture at its workplaces, Zoetis received eight awards. The report also highlights progress made since 2020 toward the company's diversity, equity and inclusion (DE&I) aspirations for 2025. In addition, colleagues at Zoetis have the opportunity for continued growth and development through annual talent reviews, development and leadership training, and mentorship and coaching. In 2023, the Leading@Zoetis program was expanded and delivered both virtually and in-person, reaching over 2,000 leaders in eight languages around the world with tools to effectively assess, coach and lead their teams. The program also offers supplemental well-being and mentoring learnings for leaders.

    Animals - Innovation in Animal Health

    Because healthy animals are more productive with reduced mortality rates, improving the health of livestock can contribute to the economic well-being of farmers and communities, support global food security, and play a role in reducing greenhouse gas emissions per unit of food produced from livestock systems. In 2023, Zoetis launched new diagnostic, vaccine and parasiticide solutions for livestock producers to support their health and productivity goals. These products included:

    • Vetscan Mastigram+™ to enable timely detection of infection and appropriate use of antimicrobials to treat mastitis in dairy cattle across international markets,
    • Valcor™ in the United States (branded as Dectomax V® in Australia and New Zealand) to help veterinarians and producers protect cattle against resistant gastrointestinal parasites,
    • Fostera® Gold PCV MH vaccine to protect pigs from respiratory disease in additional global markets, and
    • ALPHA JECT® Moritella vaccine to protect against winter ulcers in Atlantic salmon in Norway.

    Collaborations across the value chain continue to be instrumental, and in 2023, Zoetis initiated a project with Dairy Management Incorporated (DMI) and the Ruminant Farm Systems (RuFaS) modeling team to augment the development and testing of the RuFaS on-farm emissions model. Zoetis contributes animal health and genetics data for the project, as well as supportive research expertise to enable comprehensive modeling of dairy farm carbon footprints. The work continues into 2024 and represents an opportunity to understand levers that can improve the efficiency and environmental impact of milk production.

    Continuing to build on five years of its African Livestock Productivity and Health Advancement (A.L.P.H.A.) initiative, in 2023 with continued support from the Bill & Melinda Gates Foundation (BMGF), Zoetis launched a new five-year initiative. A.L.P.H.A. Plus expands the initial program's reach to seven additional African countries with focus on cattle and aquaculture in addition to poultry. The new initiative aims to increase access to an expanded portfolio of veterinary products and services, including diagnostics, and improve the scale of delivery networks for livestock farmers in Sub-Saharan Africa. Through the end of 2023, Zoetis has trained over 35,000 farmers, veterinary professionals, distributors and lab personnel, and treated 12.7 million cows and 260 million chickens in the region - exceeding goals by 27% and 30% respectively.

    Planet – the Drive to Protect our Planet

    Focused on Scope 1 and 2 emissions from its manufacturing, distribution and research and development (R&D) operations, office locations and fleet vehicles, Zoetis continues to progress toward carbon neutrality in its own operations by 2030 by:

    • Expanding its renewable energy portfolio which includes multiple utility programs, seven photovoltaic solar arrays installed at key manufacturing and R&D sites, and now two virtual power purchase agreements (VPPAs) due to come online within the next 2 years,
    • Reporting 32.6% renewable electricity sourced by the end of 2023, aligned with its RE100 commitment. More than one-third of the company's manufacturing sites operate with 100% renewable electricity,
    • Completing 38 energy efficiency and other carbon reduction projects at key sites in 2023, and
    • Increasing hybrid and electric vehicles to represent 12.1% and 3.1%, respectively, of its total vehicle fleet.

    Collectively these investments, combined with operational changes made since 2021, have reduced the company's Scope 1 and 2 emissions by 18.9%.

    Finally, as part of its packaging strategy, Zoetis continued to take substantive steps to improve its products' environmental impact in ways most important to customers and the company's footprint. At one of its key manufacturing sites, in Lincoln, Nebraska, plastic clamshells were replaced with paperboard boxes for rabies vaccine packages distributed in the U.S. market, cutting PVC plastic use by an estimated 8.0 metric tons and overall packaging by an estimated 2.5 metric tons annually.

    For more detailed disclosure on the company's sustainability programs, practices and policies, please see zoetis.com/sustainability or download Zoetis' 2023 Sustainability Report. Zoetis will continue to share updates on its sustainability activities, including progress against its Driven to Care goals, and report annually.

    About Zoetis

    As the world's leading animal health company, Zoetis is driven by a singular purpose: to nurture our world and humankind by advancing care for animals. After innovating ways to predict, prevent, detect, and treat animal illness for more than 70 years, Zoetis continues to stand by those raising and caring for animals worldwide – from veterinarians and pet owners to livestock farmers and ranchers. The company's leading portfolio and pipeline of medicines, vaccines, diagnostics and technologies make a difference in over 100 countries. A Fortune 500 company, Zoetis generated revenue of $8.5 billion in 2023 with approximately 14,100 employees. For more information, visit www.zoetis.com.

    DISCLOSURE NOTICES

    Forward-Looking Statements: This press release and the 2023 Sustainability Report (including the 2023 SASB and ESG Index) contain forward-looking statements which reflect the current views of Zoetis with respect to: our progress toward our Driven to Care aspirations; our business plans or prospects; expectations regarding future operating or financial performance; the plans and future work of the Zoetis Foundation, and other future events. These statements are not guarantees of future performance or actions. Forward-looking statements are subject to risks and uncertainties. If one or more of these risks or uncertainties materialize, or if management's underlying assumptions prove to be incorrect, actual results may differ materially from those contemplated by a forward-looking statement. Forward-looking statements speak only as of the date on which they are made. Zoetis expressly disclaims any obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise. A further list and description of risks, uncertainties and other matters can be found in our most recent Annual Report on Form 10-K, including in the sections thereof captioned "Forward-Looking Statements and Factors That May Affect Future Results" and "Item 1A. Risk Factors," in our Quarterly Reports on Form 10-Q and in our Current Reports on Form 8-K. These filings and subsequent filings are available online at www.sec.gov, www.zoetis.com, or on request from Zoetis.

    All trademarks are the property of Zoetis Services LLC or a related company or a licensor unless otherwise noted.

    See the footnotes within our 2023 Sustainability Report for more details regarding all calculations.

    © 2024 Zoetis Services LLC. All rights reserved.

    ZTS-COR

    ZTS-IR

    View source version on businesswire.com: https://www.businesswire.com/news/home/20240605298853/en/

    Get the next $ZTS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ZTS

    DatePrice TargetRatingAnalyst
    1/22/2026$135.00Overweight → Neutral
    Piper Sandler
    12/15/2025$135.00Buy → Neutral
    BofA Securities
    12/9/2025$136.00Equal Weight
    Barclays
    11/21/2025Sector Weight
    KeyBanc Capital Markets
    7/17/2025$155.00Outperform → Market Perform
    Leerink Partners
    6/18/2025$160.00Buy → Hold
    Stifel
    12/2/2024$215.00Outperform
    Leerink Partners
    7/25/2024$220.00Buy
    BTIG Research
    More analyst ratings

    $ZTS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Executive Vice President Esch Kevin

    4 - Zoetis Inc. (0001555280) (Issuer)

    2/19/26 8:54:19 PM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Sanjay Khosla

    4 - Zoetis Inc. (0001555280) (Issuer)

    2/19/26 8:54:27 PM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Tilenius Stephanie

    4 - Zoetis Inc. (0001555280) (Issuer)

    2/19/26 8:54:00 PM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ZTS
    SEC Filings

    View All

    SEC Form 144 filed by Zoetis Inc.

    144 - Zoetis Inc. (0001555280) (Subject)

    2/17/26 4:13:30 PM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-K filed by Zoetis Inc.

    10-K - Zoetis Inc. (0001555280) (Filer)

    2/12/26 4:49:26 PM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zoetis Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Zoetis Inc. (0001555280) (Filer)

    2/12/26 7:04:31 AM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ZTS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Zoetis Reports Fourth Quarter and Full Year 2025 Results

    Reports Revenue of $2.4 Billion, Growing 3%, and Net Income of $603 Million, or $1.37 per Diluted Share, Increasing 4% and 6%, Respectively, on a Reported Basis for Fourth Quarter 2025 Delivers 4% Organic Operational Growth in Revenue and 4% Organic Operational Growth in Adjusted Net Income for Fourth Quarter 2025 Reports Adjusted Net Income of $648 Million, or Adjusted Diluted EPS of $1.48, for Fourth Quarter 2025 Reports Revenue of $9.5 Billion, Growing 2%, and Net Income of $2.7 Billion, or $6.02 per Diluted Share, Increasing 8% and 10%, Respectively, on a Reported Basis for Full Year 2025 Delivers 6% Organic Operational Growth in Revenue and 7% Organic Operational Growth i

    2/12/26 7:00:00 AM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zoetis Declares Second Quarter 2026 Dividend

    The Board of Directors of Zoetis Inc. (NYSE:ZTS) has declared a dividend of $0.53 per share for the second quarter of 2026. The dividend will be paid on Tuesday, June 2, 2026, to all holders of record of the Company's common stock as of the close of business on Monday, April 20, 2026. About Zoetis As the world's leading animal health company, Zoetis is driven by a singular purpose: to nurture our world and humankind by advancing care for animals. After innovating ways to predict, prevent, detect, and treat animal illness for more than 70 years, Zoetis continues to stand by those raising and caring for animals worldwide -- from veterinarians and pet owners to livestock producers. The com

    2/5/26 4:15:00 PM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zoetis to Host Webcast and Conference Call on Fourth Quarter and Full Year 2025 Financial Results

    Zoetis Inc. (NYSE:ZTS) will host a webcast and conference call at 8:30 a.m. (ET) on Thursday, February 12, 2026. Chief Executive Officer Kristin Peck and Executive Vice President and Chief Financial Officer Wetteny Joseph will review fourth quarter and full year 2025 financial results and respond to questions from financial analysts. Investors and the public may access the live webcast by visiting the Zoetis website at http://investor.zoetis.com/events-presentations. Pre-registration for the webcast is available beginning today. A replay of the webcast will be made available on February 12, 2026. About Zoetis As the world's leading animal health company, Zoetis is driven by a singular p

    12/30/25 8:30:00 AM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ZTS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    $ZTS
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    Zoetis downgraded by Piper Sandler with a new price target

    Piper Sandler downgraded Zoetis from Overweight to Neutral and set a new price target of $135.00

    1/22/26 8:26:41 AM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zoetis downgraded by BofA Securities with a new price target

    BofA Securities downgraded Zoetis from Buy to Neutral and set a new price target of $135.00

    12/15/25 9:58:23 AM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Barclays initiated coverage on Zoetis with a new price target

    Barclays initiated coverage of Zoetis with a rating of Equal Weight and set a new price target of $136.00

    12/9/25 8:55:22 AM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    January 13, 2022 - FDA Approves Novel Treatment to Control Pain in Cats with Osteoarthritis, First Monoclonal Antibody Drug for Use in Any Animal Species

    For Immediate Release: January 13, 2022 Today, the U.S. Food and Drug Administration approved Solensia (frunevetmab injection), the first treatment for the control of pain associated with osteoarthritis in cats and the first monoclonal antibody (mAb) new animal drug approved by the FDA for use in any animal species.  Frunevetmab, the active ingredient in Solensia, is a cat-specific monoclonal antibody (a type o

    1/13/22 10:26:13 AM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ZTS
    Leadership Updates

    Live Leadership Updates

    View All

    Zoetis Announces Retirement of Rob Polzer at the End of 2025 and the Appointment of Kevin Esch as President of Research & Development for World Leader in Animal Health Beginning in 2026

    Dr. Rob Polzer to Retire at the End of the Year After 10-Year Distinguished Career of Advancing Veterinary Medicine and Innovation Zoetis Inc. (NYSE:ZTS) today announced that following a 10-year distinguished career dedicated to advancing veterinary medicine and innovation, Rob Polzer, Ph.D., Executive Vice President and President, Research and Development, has made the personal decision to retire at the end of 2025. After a planful succession process, Zoetis has appointed Kevin Esch, D.V.M, M.P.H., Ph.D., Dipl. ACVP (anatomic) to succeed Dr. Polzer in this role, effective January 1, 2026. Dr. Esch currently serves as Senior Vice President of Global Therapeutics at Zoetis and joined Zoe

    11/3/25 4:15:00 PM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zoetis Appoints Stephanie Tilenius to its Board of Directors

    Health entrepreneur brings her digital and artificial intelligence (AI) experience to Zoetis Board Zoetis Inc. (NYSE:ZTS) today announced the appointment of Stephanie Tilenius to its Board of Directors, effective as of December 1, 2025. Ms. Tilenius brings extensive experience in technology-forward, digital health organizations to the Zoetis Board. Ms. Tilenius is a serial entrepreneur and has founded several healthcare companies, including most recently a stealth company in the longevity AI space. Previously, she founded Vida Health, Inc., a leading B2B chronic care platform focusing on diabetes and obesity, and scaled it nationally for Fortune 500 companies, large payers and healthcar

    10/28/25 8:30:00 AM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Dr. Mark Stetter Elected to Zoetis Board of Directors

    Dean of the University of California, Davis School of Veterinary Medicine brings extensive and valuable experience in animal health to Zoetis Board Zoetis Inc. (NYSE:ZTS) today announced the election of Dr. Mark Stetter to its Board of Directors, effective as of the company's annual shareholder meeting on May 21, 2025. Dr. Stetter brings extensive experience in veterinary medicine and animal health, including as Dean of the University of California, Davis School of Veterinary Medicine, to the Zoetis Board. His career in animal health includes pets, livestock, exotic animals, research and wildlife. He will serve on the Board's Quality and Innovation Committee. "Dr. Stetter brings invaluab

    5/22/25 4:15:00 PM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ZTS
    Financials

    Live finance-specific insights

    View All

    Zoetis Reports Fourth Quarter and Full Year 2025 Results

    Reports Revenue of $2.4 Billion, Growing 3%, and Net Income of $603 Million, or $1.37 per Diluted Share, Increasing 4% and 6%, Respectively, on a Reported Basis for Fourth Quarter 2025 Delivers 4% Organic Operational Growth in Revenue and 4% Organic Operational Growth in Adjusted Net Income for Fourth Quarter 2025 Reports Adjusted Net Income of $648 Million, or Adjusted Diluted EPS of $1.48, for Fourth Quarter 2025 Reports Revenue of $9.5 Billion, Growing 2%, and Net Income of $2.7 Billion, or $6.02 per Diluted Share, Increasing 8% and 10%, Respectively, on a Reported Basis for Full Year 2025 Delivers 6% Organic Operational Growth in Revenue and 7% Organic Operational Growth i

    2/12/26 7:00:00 AM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zoetis Declares Second Quarter 2026 Dividend

    The Board of Directors of Zoetis Inc. (NYSE:ZTS) has declared a dividend of $0.53 per share for the second quarter of 2026. The dividend will be paid on Tuesday, June 2, 2026, to all holders of record of the Company's common stock as of the close of business on Monday, April 20, 2026. About Zoetis As the world's leading animal health company, Zoetis is driven by a singular purpose: to nurture our world and humankind by advancing care for animals. After innovating ways to predict, prevent, detect, and treat animal illness for more than 70 years, Zoetis continues to stand by those raising and caring for animals worldwide -- from veterinarians and pet owners to livestock producers. The com

    2/5/26 4:15:00 PM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zoetis to Host Webcast and Conference Call on Fourth Quarter and Full Year 2025 Financial Results

    Zoetis Inc. (NYSE:ZTS) will host a webcast and conference call at 8:30 a.m. (ET) on Thursday, February 12, 2026. Chief Executive Officer Kristin Peck and Executive Vice President and Chief Financial Officer Wetteny Joseph will review fourth quarter and full year 2025 financial results and respond to questions from financial analysts. Investors and the public may access the live webcast by visiting the Zoetis website at http://investor.zoetis.com/events-presentations. Pre-registration for the webcast is available beginning today. A replay of the webcast will be made available on February 12, 2026. About Zoetis As the world's leading animal health company, Zoetis is driven by a singular p

    12/30/25 8:30:00 AM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ZTS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Zoetis Inc. (Amendment)

    SC 13G/A - Zoetis Inc. (0001555280) (Subject)

    2/13/24 5:17:36 PM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Zoetis Inc. (Amendment)

    SC 13G/A - Zoetis Inc. (0001555280) (Subject)

    1/26/24 11:49:41 AM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Zoetis Inc. (Amendment)

    SC 13G/A - Zoetis Inc. (0001555280) (Subject)

    2/9/23 11:37:19 AM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care